Breaking News Instant updates and real-time market news.

KBR

KBR

$17.26

0.07 (0.41%)

05:55
04/12/18
04/12
05:55
04/12/18
05:55

KBR awarded LBED contract by ENAP Refinerias in Chile

KBR announced that it has been awarded a license and engineering, or LBED, contract by ENAP Refinerias SA, or ENAP, to utilize KBR's ROSE solvent deasphalting technology at their Bio Bio refinery in Concepcion, Chile. Under the terms of the contract, KBR will provide technology licensing and basic engineering design, or LBED, for ENAP's upcoming refinery upgrading project in Concepcion. ENAP will be using KBR's proprietary ROSE solvent deasphalting technology for their 30,000 BPSD plant. The ROSE unit will split residue from a mix of crude oils into deasphalted oil, or DAO, and asphaltene, allowing the refinery to upgrade a larger proportion of its oil intake into high-grade products. The new unit will not change the refinery's total processing capacity but will allow a different product mix and will give the refinery more flexibility to respond to market developments and reduce the environmental footprint of its products.

  • 26

    Apr

  • 14

    Jun

  • 25

    Jun

KBR KBR
$17.26

0.07 (0.41%)

11/01/17
DADA
11/01/17
DOWNGRADE
Target $22
DADA
Neutral
KBR downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Brent Thielman downgraded KBR Inc to Neutral from Buy but raised his price target to $22 from $20. Thielman says KBR shares are now at year-to-date high, adding that while the government services work awards provides some 2018 visibility, the Engineering & Construction segment target is contingent on the company winning more small to mid-size projects between now and first half of 2018. The analyst also notes some "noise" from ongoing litigation activity, concluding that shares are now valued more fairly given less certainty around the near-term upside catalysts.
02/26/18
DBAB
02/26/18
NO CHANGE
Target $19
DBAB
Buy
KBR 16% selloff Friday overdone, says Deutsche Bank
Deutsche Bank analyst Chad Dillard lowered his price target for KBR to $19 from $23 but views the recent share selloff as overdone. The stock fell 16% on Friday on concerns that KBR will need to use its balance sheet to fund a distressed project and that management guided 2018 earnings too aggressively, Dillard tells investors in a research note. The analyst views the likelihood of an equity raise as very low and believes the 2018 guidance is "very achievable." He thinks the shares overshot to the downside and keeps a Buy rating on KBR.
02/26/18
DADA
02/26/18
NO CHANGE
Target $17.5
DADA
Neutral
KBR price target lowered to $17.50 from $22 at DA Davidson
DA Davidson analyst Brent Thielman lowered his price target on KBR to $17.50, saying that while the management is still cultivating an organization with an expanded Government Services platform and strong Technology & Consulting business, the company is faced with near-term bottlenecks. Specifically, Thielman states that the company is now funding the completion of Ichthys with its balance sheet, and the changes to completion costs pose a risk. The analyst also points to an "ongoing litigious noise and the already factored expectation E&C bookings build", keeping his Neutral rating.
02/26/18
FBCO
02/26/18
DOWNGRADE
Target $16
FBCO
Neutral
KBR downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Jamie Cook downgraded KBR to Neutral from Outperform as he believes the Ichthys problem project coupled with what is now a highly levered balance sheet and potential risk of a modest equity raise will be an overhang on the stock. The analyst also lowered his price target on the shares to $16 from $24.

TODAY'S FREE FLY STORIES

FB

Facebook

$159.69

0.03 (0.02%)

05:20
04/26/18
04/26
05:20
04/26/18
05:20
Recommendations
Facebook analyst commentary  »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERN

Erin Energy

$1.65

-0.825 (-33.33%)

05:18
04/26/18
04/26
05:18
04/26/18
05:18
Hot Stocks
Erin Energy files voluntary petitions under Chapter 11 to pursue reorganization »

Erin Energy and certain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$96.54

0.04 (0.04%)

05:16
04/26/18
04/26
05:16
04/26/18
05:16
Recommendations
Citrix analyst commentary  »

Citrix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 08

    May

  • 09

    May

AMD

AMD

$9.72

-0.37 (-3.67%)

05:13
04/26/18
04/26
05:13
04/26/18
05:13
Recommendations
AMD analyst commentary  »

AMD could see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EBAY

eBay

$40.98

-0.2 (-0.49%)

05:09
04/26/18
04/26
05:09
04/26/18
05:09
Recommendations
eBay analyst commentary  »

eBay GMV growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.71

-1.65 (-25.94%)

05:01
04/26/18
04/26
05:01
04/26/18
05:01
Downgrade
Trivago rating change  »

Trivago downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPR

HighPoint Resources

$6.65

0.14 (2.15%)

04:58
04/26/18
04/26
04:58
04/26/18
04:58
Initiation
HighPoint Resources initiated  »

HighPoint Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

AVY

Avery Dennison

$106.68

1.195 (1.13%)

04:57
04/26/18
04/26
04:57
04/26/18
04:57
Upgrade
Avery Dennison rating change  »

Avery Dennison upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/21 Jobless…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/25 Fed Balance…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

WYN

Wyndham

$117.67

1.83 (1.58%)

, LQ

La Quinta

$19.70

0.08 (0.41%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
La Quinta to host special shareholder meeting »

Special Shareholder…

WYN

Wyndham

$117.67

1.83 (1.58%)

LQ

La Quinta

$19.70

0.08 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/16 Money Supply…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

March International Trade…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Wholesale Inventories [Advance] M/M % hange to be reported at 08:30 »

March Wholesale…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/20 EIA Natural…

SMMT

Summit Therapeutics

$13.66

0.13 (0.96%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Summit Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

ABBV

AbbVie

$91.91

0.57 (0.62%)

, ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
American Academy of Neurology to hold annual meeting »

2018 Annual Meeting of…

ABBV

AbbVie

$91.91

0.57 (0.62%)

ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

ALXN

Alexion

$106.07

-0.37 (-0.35%)

AKCA

Akcea Therapeutics

$26.85

0.02 (0.07%)

RHHBY

Roche

TEVA

Teva

$17.27

-0.28 (-1.60%)

UBS

UBS

$16.78

-0.095 (-0.56%)

MDT

Medtronic

$79.47

0.12 (0.15%)

MCK

McKesson

$151.70

2.76 (1.85%)

NVTA

Invitae

$5.53

-0.15 (-2.64%)

IONS

Ionis Pharmaceuticals

$43.98

-1.35 (-2.98%)

IPXL

Impax

$19.25

-0.65 (-3.27%)

DNA

Bought by RHHBY

DGX

Quest Diagnostics

$101.17

1.42 (1.42%)

ESALY

Eisai

DEPO

Depomed

$6.66

-0.17 (-2.49%)

CPRX

Catalyst Pharmaceuticals

$2.64

0.04 (1.54%)

BSX

Boston Scientific

$29.44

1.01 (3.55%)

BMRN

BioMarin

$81.41

0.33 (0.41%)

MYL

Mylan

$38.93

-1.32 (-3.28%)

NBIX

Neurocrine

$78.13

-0.3 (-0.38%)

NVS

Novartis

$76.42

-0.58 (-0.75%)

PFE

Pfizer

$36.69

-0.36 (-0.97%)

RARX

RA Pharmaceuticals

$5.76

-0.2 (-3.36%)

SNY

Sanofi

$40.11

0.335 (0.84%)

SYK

Stryker

$165.44

0.77 (0.47%)

SUPN

Supernus

$47.30

0.55 (1.18%)

LLY

Eli Lilly

$81.17

1.08 (1.35%)

BAYRY

Bayer

AMGN

Amgen

$174.83

2.92 (1.70%)

ALNY

Alnylam

$94.35

-0.34 (-0.36%)

BIIB

Biogen

$269.47

7.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 16

    Jun

  • 06

    Jul

  • 11

    Aug

  • 12

    Sep

  • 05

    Oct

  • 20

    Oct

  • 13

    Nov

  • 28

    Jan

SCPH

scPharmaceuticals

$9.92

-0.1 (-1.00%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
scPharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    Jun

ALNA

Allena Pharmaceuticals

$14.77

0.845 (6.07%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RIO

Rio Tinto

$55.24

-0.44 (-0.79%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Rio Tinto management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/22 Bloomberg…

SPNE

SeaSpine

$11.05

-0.11 (-0.99%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
SeaSpine management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.